As New Jersey’s only NCI-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health, provides patients access to the most advanced treatment options including complex surgical procedures, sophisticated radiation therapy techniques, innovative clinical trials, immunotherapy, and precision medicine.
|
|
|
October is Breast Cancer Awareness Month: Rutgers Cancer Institute Experts Provide an Update on Advances in Research, Treatment and Diagnosis |
|
|
|
October is Breast Cancer Awareness Month, a time to increase awareness about the second leading cause of cancer deaths in women according to the American Cancer Society. Experts from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health share the latest on breast cancer research, treatment and prevention. Learn more from Deborah Toppmeyer, MD, chief medical officer and director of the Stacy Goldstein Breast Cancer Center and LIFE Center; Bruce Haffty, MD, MS, chair of Radiation Oncology and associate vice chancellor for Cancer Programs at Rutgers Cancer Institute and system director of Radiation Oncology at RWJBarnabas Health; Lindsay Potdevin, MD, surgical oncologist at Rutgers Cancer Institute and Robert Wood Johnson University Hospital Somerset, an RWJBarnabas Health facility; and Elisa V. Bandera, MD, PhD, chief of Cancer Epidemiology and Health Outcomes and co-leader of the Cancer Prevention and Control Program at Rutgers Cancer Institute. Learn more
|
|
Exploring New Therapies for Liver Cancer |
|
|
|
Hepatocellular carcinoma (HCC), the most common type of liver cancer, is the fastest-increasing cancer-related cause of death in the United States with very limited treatment options. Kristen Spencer, DO, MPH, medical oncologist in the Liver Cancer and Bile Duct Cancer Program and Phase I/Investigational Therapeutics Program at Rutgers Cancer Institute of New Jersey and an assistant professor of medicine at Rutgers Robert Wood Johnson Medical School, is principal investigator on a project exploring a drug combination for the treatment of HCC. The study is being conducted in collaboration with participating sites throughout the Big Ten Cancer Research Consortium. Learn more
|
|
Big Ten Cancer Research Consortium Highlights Coral Omene, MD, PhD for Her Work with Breast Cancer Clinical Trials |
|
|
|
As part of the Big Ten Cancer Research Consortium, Rutgers Cancer Institute of New Jersey physicians and researchers work collaboratively with peers at Big Ten universities to bring the most innovative care to patients through cutting-edge clinical trials. Coral Omene, MD, PhD, medical oncologist at Rutgers Cancer Institute and assistant professor of medicine at Rutgers Robert Wood Johnson Medical School, was highlighted as a feature member this month for her work with the Consortium. Dr. Omene has a passion for women’s health and is dedicated to the care of treating and managing a diverse pool of breast cancer patients. Read more
|
|
Exploring the Impact of Blood Clots in the Veins during Kidney Cancer Surgery |
|
|
|
Venous thromboembolism (VTE) refers to blood clots in the veins, which is a serious yet preventable medical condition and is often seen with advanced cancers. Hiren V. Patel, MD, PhD, Rutgers Robert Wood Johnson Medical School urology resident, along with senior author Eric A. Singer, MD, MA, MS, FACS, FASCO, associate chief of urology and director of the Kidney Cancer Program at Rutgers Cancer Institute, and associate professor of surgery and radiology at Rutgers Robert Wood Johnson Medical School and colleagues explored the impact of VTE during surgery for renal cell carcinoma, also known as kidney cancer. Results of the work were presented as a poster at the American Urological Association 2021 Annual Meeting in Las Vegas, Nevada. Learn more
|
|
|
|
|
|
|
